Latest news with #IDN
Yahoo
27-05-2025
- Business
- Yahoo
What Makes Intellicheck Mobilisa, Inc. (IDN) a Strong Momentum Stock: Buy Now?
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at Intellicheck Mobilisa, Inc. (IDN), a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Intellicheck Mobilisa, Inc. Currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period. You can see the current list of Zacks #1 Rank Stocks here >>> In order to see if IDN is a promising momentum pick, let's examine some Momentum Style elements to see if this company holds up. Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area. For IDN, shares are up 35.8% over the past week while the Zacks Security and Safety Services industry is down 2.97% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 76.54% compares favorably with the industry's 5.66% performance as well. While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Intellicheck Mobilisa, Inc. Have risen 80.71%, and are up 46.18% in the last year. On the other hand, the S&P 500 has only moved -3.17% and 11.56%, respectively. Investors should also take note of IDN's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, IDN is averaging 390,918 shares for the last 20 days. The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with IDN. Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost IDN's consensus estimate, increasing from -$0.03 to -$0.01 in the past 60 days. Looking at the next fiscal year, 2 estimates have moved upwards while there have been no downward revisions in the same time period. Given these factors, it shouldn't be surprising that IDN is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Intellicheck Mobilisa, Inc. On your short list. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intellicheck Mobilisa, Inc. (IDN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
21-05-2025
- Business
- Yahoo
DA Davidson upgrades Intellicheck with growth acceleration ‘now in sight'
DA Davidson upgraded Intellicheck (IDN) to Buy from Neutral with a price target of $5.50, up from $3, after the company announced a new contract expansion with a Southeast regional bank with a low seven-figure initial annual contract value and a 'very high' seven-figure total contract value over three years. The additional contracted revenue is expected to begin flowing in Q3, notes the analyst, who is raising calendar year 2025 and 2026 growth estimates by 2 points and 6 points, respectively, following the contract announcement. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on IDN: Disclaimer & DisclosureReport an Issue Intellicheck upgraded to Buy from Neutral at DA Davidson Intellicheck reports three-year, seven-figure agreement with financial customer Intellicheck's Positive Earnings Call Highlights Growth and Challenges Intellicheck Mobilisia: Strategic Diversification and Cost Management Drive Buy Rating Amid Growth Potential Intellicheck Reports Record Q1 2025 Revenue Growth
Associated Press
10-03-2025
- Business
- Associated Press
Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System
The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif., March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer, received 510(k) clearance from the U.S. Food and Drug Administration. The DxC 500i combines advanced technology with an intuitive user interface, ensuring that laboratories of all sizes can meet the growing demands of modern healthcare. With throughput of up to 800 clinical chemistry tests per hour and 100 immunoassay tests per hour, this analyzer delivers precise and reliable results critical for timely clinical decision-making. Healthcare systems around the world and specifically in the United States are strategically adopting networked laboratory operational models for better efficiency and patient access. Approximately 45% of clinical laboratories in the United States — a total of more than 11,000 labs — are associated with an Integrated Delivery Network (IDN).i IDNs are organizations that provide a coordinated range of healthcare services, including diagnostic testing allowing for better resource management, standardized practices, and enhanced quality of care. 'Innovations like the DxC 500i Clinical Analyzer enable Beckman Coulter to address the needs of networked laboratories with specific solutions for satellite or independent laboratories, as well as core laboratories,' said Kathleen Orland, Chief Portfolio Officer for Beckman Coulter Diagnostics. 'Beyond ensuring appropriate throughput levels for a networked lab, Beckman Coulter's common reagents and consumables across its scalable clinical chemistry and immunoassay portfolio enables common reference ranges, offering IDNs strategic benefits in patient care and inventory management.' The DxC 500i Clinical Analyzer features FlexMode operations, prioritizing immunoassay and chemistry testing according to each sample's urgency. The new dynamic sample handler manages repeats and re-runs without operator intervention and pulls in a new sample rack as soon as the previous rack is offloaded, optimizing rapid throughput in a compact footprint. Of equal importance, the DxC 500i Analyzer's intuitive interface supports even the newest users through proactive task indicators with step-by-step instructions, simplifying staff onboarding and training. The DxC 500i Clinical Analyzer has been available in countries accepting CE mark since July 2024. Prior to the DxC 500i Clinical Analyzer introduction, Beckman Coulter unveiled the DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer with onboard guided workflows, more than 120 assays, and standardized reagents for use across healthcare networks. The DxC 500i analyzer incorporates the DxC 500 AU technology within its clinical chemistry capabilities, including its Six Sigma performance. Not all products are available in all countries. Product availability and regulatory status depends on country registration per applicable regulations. Follow and connect with Beckman Coulter Diagnostics via LinkedIn, X, and Facebook. About Beckman Coulter Diagnostics A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 90 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time — and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We seek to accelerate care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and to optimize lab performance services. Headquartered in Brea, Calif., with more than 11,000 global team members, Beckman Coulter Diagnostics is proud to be part of Danaher (NYSE: DHR). Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. © 2025 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. The Danaher trademark is a proprietary mark of Danaher Corporation. All other trademarks are the property of their respective owners. 2025-14088
Yahoo
06-02-2025
- Business
- Yahoo
VSee Health Secures $2M Contract Renewal for Neurocritical Care Expansion at Leading Hospital System
Expansion Includes Autonomous Robotics and Industry-Disrupting Telenursing Model SAN JOSE, Calif., February 06, 2025--(BUSINESS WIRE)--VSee Health, Inc. (Nasdaq: VSEE), a leader in comprehensive digital health services and customized telehealth solutions, announces the successful renewal of a $2 million, two-year contract with a top 50 Integrated Delivery Network (IDN) hospital system. This renewal significantly expands the partnership, doubling the number of covered hospital beds and incorporating VSee Health's autonomous self-driving robot solutions for neurocritical care. This renewal marks a pivotal milestone for VSee Health, demonstrating the successful integration of its end-to-end digital health ecosystem—encompassing software, hardware, clinical services, and billing solutions. By leveraging this model, VSee Health is now pioneering a breakthrough telenursing solution that is set to disrupt the industry by addressing workforce shortages and enhancing care delivery efficiency. Advancing Neurocritical Care with AI and Robotics The renewed partnership underscores the growing demand for autonomous healthcare technologies and seamless telehealth integrations in critical care settings. VSee Health's self-driving robot solutions will enable real-time patient monitoring, provider collaboration, and AI-assisted care workflows—empowering hospitals to manage higher patient volumes without straining their existing workforce. "We are proud to deepen our collaboration with one of the nation's top health systems, delivering a scalable and intelligent telehealth solution that improves patient outcomes while optimizing hospital operations," said Imo Aisiku, M.D., Co-CEO of VSee Health. "This renewal solidifies the effectiveness of our comprehensive digital health stack and reinforces our commitment to shaping the future of remote and automated healthcare." Poised to Disrupt the Industry with Telenursing Building on this successful integration, VSee Health is now actively developing a revolutionary telenursing model designed to combat critical nursing shortages and burnout while maintaining high-quality patient care. By combining AI-driven automation, remote nursing support, and robotic assistance, VSee Health is setting a new standard for hospitals seeking to streamline operations without compromising care quality. About VSee Health VSee Health (Nasdaq: VSEE) is a rapidly growing leader in AI-powered telehealth, redefining the $787 billion digital healthcare market with its modular, no-code/low-code platform. Trusted by 1,000+ clients, including NASA, the U.S. Department of Health and Human Services, McKesson, DaVita, and the entire nation of Qatar, VSee Health accelerates telehealth adoption by enabling seamless, scalable, and secure digital health solutions across hospitals, governments, and enterprise organizations. Field-tested with 1.5 million+ HIPAA-compliant video encounters per month, VSee Health delivers turnkey solutions in critical care, teleradiology, and autonomous robotics, optimizing healthcare operations while increasing billable patient visits and provider efficiency. With a clear path to significant revenue growth and expanding margins, VSee Health is positioned to become the foundational infrastructure of digital healthcare, transforming patient care, hospital workflows, and workforce utilization. Visit for more information. Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as "believes," "expects, "intends," "plans," "estimates," "assumes," "may," "should," "will," "seeks," or other similar expressions. Such statements may include, but are not limited to, statements regarding the Company's ability to regain compliance with Nasdaq's listing rules within the required timeframe. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly, including those risks set forth in the Company's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q and other documents filed with the SEC. Copies of such filings are available on the SEC's website at The Company does not assume any obligation to update or revise any such forward- looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements. View source version on Contacts Media Contact: VSee HealthAnne Chang626-513-1824media@ Investor Contact: Dave GentryRedChip Companies1-407-644-4256VSEE@ Sign in to access your portfolio
